Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovac depot in Parietaria judaica sensitized rhinoconjunctivitis
NCT02477917Phase 1Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- May 2015
- Primary completion
- Mar 2016
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of parietaria judaica pollen extract in allergic rhinoconjunctivitis (ARC), sponsored by ROXALL Medizin GmbH. Primary endpoint: Number and severity of adverse reactions at 17 weeks. Started May 2015; status: completed.
02
Drugs
parietaria judaica pollen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02477917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477917.